Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition
Malavika Deodhar(Research & Development Institute), Véronique Michaud(Research & Development Institute), Lucy I. Darakjian(Research & Development Institute), Sweilem B. Al Rihani(Moderna Therapeutics (United States)), Jacques Turgeon(Unknown)
Cited by 91
Related Papers
Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
|Pharmaceutics|2020|237
Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy
|Annals of Pharmacotherapy|2013|186
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
|PubMed|1999|177